CEL-SCI Reports Fiscal Second Quarter 2026 Results
CEL-SCI Announces Closing of Public Offering
CEL-SCI Corporation Announces Pricing of Public Offering
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
Itaú Unibanco Holding files 2025 Form 20-F with the SEC and the CVM
Cel-Sci (NYSEAMERICAN:CVM) Shares Down 0.9% – What’s Next?
Cel-Sci (NYSEAMERICAN:CVM) Stock Price Up 6.9% – Time to Buy?
CEL-SCI Reports Fiscal First Quarter 2026 Results
Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 6.5% – What’s Next?
CEL-SCI Reports Fiscal 2025 Results
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025
CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference
Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension
CEL-SCI Announces Closing of $10 Million Public Offering
CEL-SCI Announces Pricing of $10 Million Public Offering
CEL-SCI Announces Proposed Public Offering
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
CEL-SCI Announces Closing of Public Offering
CEL-SCI Announces Pricing of Public Offering
CEL-SCI Announces Proposed Public Offering
CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
CEL-SCI Announces Combination of Common Stock
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
CEL-SCI Announces Closing of $2.5 Million Offering
CEL-SCI Announces Pricing of $2.5 Million Offering
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
CEL-SCI Announces Closing of $5 Million Offering
CEL-SCI Announces Pricing of $5 Million Public Offering
CEL-SCI Announces Proposed Public Offering of Common Stock
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
Stock Picks From Seeking Alpha's October 2024 New Analysts
FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content
CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology